GE Healthcare continues to ramp up its offerings in the bioprocessing space with the purchase of Asymptote and a continued partnership with Zenith Technologies.
Randi Hernandez
Advertisement
Randi Hernandez was science editor at BioPharm International from September 2014 to May 2017.
Articles by Randi Hernandez
The mAb is the first approved treatment that targets the progressive form of the disease.
A new FDA Q&A document released on Jan. 12, 2016 describes 180-day exclusivity for generic-drug manufacturers and explains the number of conditions under which an abbreviated new drug applicant (ANDA) submitting a paragraph IV certification would forfeit eligibility to be the authorized generic manufacturer of a drug.
Advertisement
Latest Updated Articles
- FDA Clarifies How It Handles 180-Day Exclusivity
Published: January 18th 2017 | Updated:
- FDA Approves First Treatment for Primary-Progressive Forms of Multiple Sclerosis
Published: March 29th 2017 | Updated:
- GE Healthcare: The Next Cell and Gene Therapy Manufacturing Giant?
Published: April 11th 2017 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Standardizing Operations to Meet Global Sustainability and Resilience Goals
2
Drug Digest: Strategic Alliances and Technology Integration in the Evolving Biopharma Landscape
3
Takeda’s Sriman Banerjee Discusses Smart Packaging at CPHI Frankfurt 2025
4
Clearing Hurdles in Sustainability, AI, and CDMO Partnerships
5
